



**PATENT**  
Attorney Docket No. **UM-06191**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Blake J. Roessler *et al.*

Serial No.: 09/867,927

Group No.:

Filed: 05/30/01

Examiner:

Entitled: **Delivery Systems Comprising Biocompatible  
And Bioerodable Membranes**

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 29, 2002.

By: 

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications are referred to in the body of the specification:

- U.S. Patent No. 4,507,466
- U.S. Patent No. 4,558,120
- U.S. Patent No. 4,568,737
- U.S. Patent No. 4,587,329
- U.S. Patent No. 4,631,337
- U.S. Patent No. 4,694,064
- U.S. Patent No. 4,713,975
- U.S. Patent No. 4,737,550
- U.S. Patent No. 4,857,599

- U.S. Patent No. 4,871,779
- U.S. Patent No. 5,338,532
- U.S. Patent No. 5,387,617
- U.S. Patent No. 5,393,797
- U.S. Patent No. 5,393,795
- U.S. Patent No. 5,527,524
- U.S. Patent No. 5,560,929
- U.S. Patent No. 5,773,527
- U.S. Patent No. 5,631,329
- U.S. Patent No. 5,902,863
- U.S. Patent No. 5,795,582
- U.S. Patent No. 5,898,005
- U.S. Patent No. 5,861,319
- U.S. Patent No. 5,661,025
- U.S. Patent No. 4,965,128
- U.S. Patent No. 4,161,948
- EP 0099758

and

- Gerwitz *et al.*, Blood 92:712 [1998]
- Ye *et al.*, Mol Med Today 4:431 [1998]
- Tomalia *et al.*, Agnew Chem Int Ed Engl 29:138 [1990];
- Frechet, Science 263:1710 [1994]].
- Kukowska-Latallo *et al.*, Proc Natl Acad Sci USA 93:4897 [1996]
- Bielinska *et al.*, Nucleic Acids res 24:2176 [1996]
- Roberts *et al.*, J Biomed Mater res 30:53 [1996]
- Choate *et al.*, Human Gene Ther 8:1659 [1997]
- Trainer *et al.*, Human Mol Gen 6:1761 [1997];
- Jain *et al.*, Drug Dev Ind Pharm 24:703 [1998])
- Luck *et al.*, J. Control Rel 55:107 [1998]
- Webber *et al.*, J. Biomed Mater Res 41:18 [1998];
- Garcia-Contreras *et al.*, Pharm Dev Tech 2:53 [1997]

- Tomalia, Advanced Materials 6:529 [1994]
- Yin *et al.*, J. Am. Chem. Soc., 120:2678 [1998]
- Bourne *et al.*, J. Magn. Reson. Imag., 6:305 [1996]
- Singh *et al.*, Clin. Chem., 40:1845 [1994]
- Wu *et al.*, Bioorg. Med. Chem. Lett., 4:449 [1994]
- Wiener *et al.*, Magn. Reson. Med. 31:1 [1994]
- Barth *et al.*, Bioconjugate Chem. 5:58 [1994]
- Duncan and Malik, Control Rel. Bioact. Mater. 23:105 [1996]
- Baker *et al.*, Anal. Chem. 69:990 [1997]
- Urdea and Hom, Science 261:534 [1993]
- Pavlova *et al.*, Biomaterials 14(13):1024 [1993]
- Sottosanti, Compendium 13(3):226-8, 230, 232-4 [1992];
- Brandl *et al.*, Adv Biochem Eng Biotechnol ;41:77 [1990]
- Braunegg *et al.*, J Biotechnol 65(2-3):127 [1998]
- Gac *et al.*, J Drug Target 7(5):393 [2000]
- Mayer *et al.*, J Controlled Release 64(1-3):81 [2000]
- Madhally and Matthew, Biomaterials 20(12):1133 [1999]
- Folkman *et al.*, Science, 235:442 [1987]
- Folkman *et al.*, Journ. of Biol. Chem., 267(16):10931 [1992]
- Fidler *et al.*, Cell, 79:185 [1994]
- Folkman, New Eng. J. Med., 333(26):1757 [1995]
- Levi-Montalcini, *In Vitro* Cell. Devel. Biol. 23:227 [1987]
- Jane *et al.*, Annals of Med 30:413 [1998]
- Niemiec *et al.*, J. Pharm. Sci. 86:701 [1997]
- Yew *et al.*, Human Gene. Ther., 8:575 [1997]
- Raczka *et al.*, Gene Ther 5:1333 [1998];
- Baumann *et al.*, J. Histochem. Cytochem., 46:1073 [1998]
- Tang *et al.*, Bioconjug Chem 7:703 [1996]
- Bielinska *et al.*, Biochim Biophys Acta 1353:180 [1997]
- Bielinska *et al.*, Bioconj Chem 10:843 [1999]
- Winter, Nature 193:293 [1962]

- Kannon and Garrett, Dermatol. Surg. 21:583 (1995)
- Davies, Burns 10:94 (1983)
- Riley, Am. Fam. Physician 24:107 (1981)

The below references were cited in the corresponding PCT International Application No. PCT/01/40824 International Search Report.

- WO 99/58656
- WO 95/24221
- Bielinska *et al.*, Biomaterials 41:881-887 (2000)
- Malik *et al.*, Journal of Controlled Relief 65:133-148 (2000)
- Roessler *et al.*, Biochem. 124-129 (2001)
- Shea, Nature 17:551-554 (1999)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: May 29, 2002



Thomas J. Bordner  
Registration No. 47,436

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 305  
San Francisco, California 94105  
415/904-6500

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06191

Serial No.: 09/867,927

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Blake J. Roessler *et al.*

Filing Date: 05/30/01

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,507,466	03-26-85	Tomalia et al.	528	332	01-07-83
	2	4,558,120	12-10-85	Tomalia et al.	528	363	12-27-83
	3	4,568,737	02-04-86	Tomalia et al.	528	332	08-17-84
	4	4,587,329	05-06-86	Tomalia et al.	528	363	07-19-85
	5	4,631,337	12-23-86	Tomalia et al.	528	391	07-15-85
	6	4,694,064	09-15-87	Tomalia et al.	528	332	02-28-86
	7	4,713,975	12-22-87	Tomalia et al.	73	865.8	05-30-86
	8	4,737,550	04-12-88	Tomalia	524	418	12-08-86
	9	4,857,599	08-15-89	Tomalia et al.	525	259	02-08-88
	10	4,871,779	10-03-89	Killat et al.	521	28	12-23-85
	11	5,338,532	08-16-94	Tomalia et al.	424	1.49	02-13-91
	12	5,387,617	02-07-95	Hedstrand et al.	521	79	11-08-93
	13	5,393,797	02-28-95	Hedstrand et al.	521	134	06-13-94
	14	5,393,795	02-28-95	Hedstrand et al.	521	134	06-13-94
	15	5,527,524	06-18-96	Tomalia et al.	424	1.33	04-05-93
	16	5,560,929	10-01-96	Hedstrand et al.	424	486	11-12-93
	17	5,773,527	06-30-98	Tomalia et al.	525	417	01-20-95
	18	5,631,329	05-20-97	Yin et al.	525	417	03-21-95
	19	5,902,863	05-11-99	Dvornic et al.	525	431	07-21-97
	20	5,795,582	08-18-98	Wright	424	400	02-07-96
	21	5,898,005	04-27-99	Singh et al.	436	527	04-13-94
	22	5,861,319	01-19-99	Lin et al.	436	527	10-28-94
	23	5,661,025	08-26-97	Szoka, Jr. et al.	435	458	06-07-95
	24	4,965,128	10-23-90	Greidanus et al.	428	398	02-26-88
	25	4,161,948	07-24-79	Bichon	602	58	01-16-78

**FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS**

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	26	EP0099758						
	27	WO 99/58656						
	28	WO 95/24221						

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

	29	Winter, Nature 193:293 [1962]
	30	Kannon and Garrett, Dermatol. Surg. 21:583 [1995]

Examiner:

Date Considered:

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-06191	Serial No.: 09/867,927
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: Blake J. Roessler <i>et al.</i>	
				Filing Date: 05/30/01	Group Art Unit:
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Applicant's Title, Date, Relevant Pages, Place of Publication)					
31	Davies, Burns 10:94 [1983]				
32	Riley, Am. Fam. Physician 24:107 [1981]				
33	Ye <i>et al.</i> , Mol Med Today 4:431 [1998]				
34	Gerwitz <i>et al.</i> , Blood 92:712 [1998]				
35	Tomalia <i>et al.</i> , Agnew Chem Int Ed Engl 29:138 [1990]				
36	Frechet, Science 263:1710 [1994]				
37	Kukowska-Latallo <i>et al.</i> , Proc Natl Acad Sci USA 93:4897 [1996]				
38	Bielinska <i>et al.</i> , Nucleic Acids res 24:2176 [1996]				
39	Roberts <i>et al.</i> , J Biomed Mater res 30:53 [1996]				
40	Choate <i>et al.</i> , Human Gene Ther 8:1659 [1997]				
41	Trainer <i>et al.</i> , Human Mol Gen 6:1761 [1997]				
42	Jain <i>et al.</i> , Drug Dev Ind Pharm 24:703 [1998]				
43	Luck <i>et al.</i> , J. Control Rel 55:107 [1998]				
44	Webber <i>et al.</i> , J. Biomed Mater Res 41:18 [1998]				
45	Garcia-Contreras <i>et al.</i> , Pharm Dev Tech 2:53 [1997]				
46	Tomalia, Advanced Materials 6:529 [1994]				
47	Yin <i>et al.</i> , J. Am. Chem. Soc., 120:2678 [1998]				
48	Bourne <i>et al.</i> , J. Magn. Reson. Imag., 6:305 [1996]				
49	Singh <i>et al.</i> , Clin. Chem., 40:1845 [1994]				
50	Wu <i>et al.</i> , Bioorg. Med. Chem. Lett., 4:449 [1994]				
51	Wiener <i>et al.</i> , Magn. Reson. Med. 31:1 [1994]				
52	Barth <i>et al.</i> , Bioconjugate Chem. 5:58 [1994]				
53	Duncan and Malik, Control Rel. Bioact. Mater. 23:105 [1996]				
54	Baker <i>et al.</i> , Anal. Chem. 69:990 [1997]				
55	Urdea and Hom, Science 261:534 [1993]				
56	Pavlova <i>et al.</i> , Biomaterials 14(13):1024 [1993]				
57	Sottosanti, Compendium 13(3):226-8, 230, 232-4 [1992]				
58	Brandl <i>et al.</i> , Adv Biochem Eng Biotechnol ;41:77 [1990]				
59	Braunegg <i>et al.</i> , J Biotechnol 65(2-3):127 [1998]				
60	Gac <i>et al.</i> , J Drug Target 7(5):393 [2000]				
Examiner:				Date Considered:	
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06191

Serial No.: 09/867,927

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Blake J. Roessler *et al.*

Filing Date: 05/30/01

Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

[illegible]

Examiner:

Date Considered:

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.